Venetoclax + Cytarabine
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia, AML
Trial Timeline
Dec 31, 2014 → Aug 10, 2021
NCT ID
NCT02287233About Venetoclax + Cytarabine
Venetoclax + Cytarabine is a phase 1/2 stage product being developed by AbbVie for Acute Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02287233. Target conditions include Acute Myelogenous Leukemia, AML.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04509622 | Phase 3 | Completed |
| NCT02287233 | Phase 1/2 | Completed |
Competing Products
20 competing products in Acute Myelogenous Leukemia